Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RCTS2: disitamab vedotin + sintilimab + S-1 versus trastuzumab + chemotherapy for first-line HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2600134282Phase 2Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of disitamab vedotin, sintilimab, tegafur and trastuzumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Objective response rate. Started Oct 2024; status: recruiting.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600134282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134282.